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Prospective studiesAbstract Aim of the study: A vast majority of human malignancies are associated with
ageing, and age is a strong predictor of cancer risk. Recently, DNA methylation-based marker
of ageing, known as ‘epigenetic clock’, has been linked with cancer risk factors. This study
aimed to evaluate whether the epigenetic clock is associated with breast cancer risk suscepti-
bility and to identify potential epigenetics-based biomarkers for risk stratification.
Methods: Here, we profiled DNA methylation changes in a nested caseecontrol study
embedded in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort
(n Z 960) using the Illumina HumanMethylation 450K BeadChip arrays and used the Hor-
vath age estimation method to calculate epigenetic age for these samples. Intrinsic epigenetic
age acceleration (IEAA) was estimated as the residuals by regressing epigenetic age on chro-
nological age.
Results: We observed an association between IEAA and breast cancer risk (OR, 1.04; 95% CI,
1.007e1.076, P Z 0.016). One unit increase in IEAA was associated with a 4% increased odds
of developing breast cancer (OR, 1.04; 95% CI, 1.007e1.076). Stratified analysis based on
menopausal status revealed that IEAA was associated with development of postmenopausal
breast cancers (OR, 1.07; 95% CI, 1.020e1.11, P Z 0.003). In addition, methylome-wide
analyses revealed that a higher mean DNA methylation at cytosine-phosphate-guanine
(CpG) islands was associated with increased risk of breast cancer development (OR per 1
SD Z 1.20; 95 %CI: 1.03e1.40, P Z 0.02) whereas mean methylation levels at non-island
CpGs were indistinguishable between cancer cases and controls.
Conclusion: Epigenetic age acceleration and CpG island methylation have a weak, but statis-
tically significant, association with breast cancer susceptibility.
ª 2017 Elsevier Ltd. All rights reserved.
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Ageing is a major risk factor for most neoplasms [1]. In
particular, breast cancer is an age-associated disease
whose incidence rises sharply after menopause [1]. This
increased risk was hypothesised to be the consequence of
accumulation of genetic changes (mutations) associated
with deregulation of cellular processes and genomic
instability. However, accumulation of genetic changes
exhibits striking interindividual differences [2], and dif-
ferences in biological ageing processes may only be
partly explained by genetic determinants [3].
A recent study demonstrates that DNA methylation
(DNAm) data lend themselves for developing a highly
accurate multitissue biomarker of ageing [4]. The
DNAm-based marker of ageing (known as ‘epigenetic
clock’) derived from several tissues can be used to
accurately estimate the chronological age of all tissues
and cell types [4]. This composite biomarker of ageing,
which is defined as a weighted average across 353 spe-
cific CpG sites, produces an estimate of age (in units of
years), referred to as ‘epigenetic age’ or ‘DNA methyl-
ation age (DNAm age)’. Recent studies demonstrate
that DNAm age is at least a passive biomarker of bio-
logical age: the epigenetic age of blood has been found
to be predictive of all-cause mortality [5e9], frailty [10],
cognitive and physical functioning [5]. Further, the
utility of the epigenetic clock method using various tis-
sues and organs has been demonstrated in applications
surrounding Alzheimer disease [11], centenarian status
[8], pre-natal and early life influences [12], Down syn-
drome [13], HIV infection [14], Huntington disease [15],
obesity [16], lifetime stress [17], menopause [18], and
Parkinson disease [19]. Departures of methylation-
estimated age from chronological age can be used to
define intrinsic epigenetic age acceleration (IEAA) that
measures cell-intrinsic ageing effects that are indepen-
dent of chronological age and blood cell composition.
A recent study suggests that IEAA can be used to
predict lung cancer risk [20]. However, it is not yet
known whether IEAA lends itself for predicting breast
cancer susceptibility in a prospective caseecontrol
study. To test this hypothesis, we analysed blood
methylation data from incident breast cancer cases and
matching controls of a large prospective study within
the European Prospective Investigation into Cancer and
Nutrition (EPIC) cohort.2. Materials and methods
2.1. Selection of incident cancer and control participants
The present study was conducted on nested caseecontrol
samples from the European Prospective Investigation
into Cancer and Nutrition (EPIC) cohort, a large pro-
spective study conducted in 23 centres across tenEuropean countries (Denmark, France, Germany,
Greece, Italy, Norway, Spain, Sweden, The Netherlands,
and the United Kingdom), aiming to investigate the
relationship between diet, lifestyle, metabolism and
cancer risk [21]. In brief, the EPIC cohort includes a total
of about 315,000 women and 200,000 men. At baseline
recruitment, all study participants provided extensive
questionnaire information about nutrition and other
lifestyle factors. All study participants also provided a
blood sample, which was processed, divided into aliquots
of plasma, serum and buffy coat and frozen at 196 C
(under liquid nitrogen) for later use in specific research
projects. In all EPIC centres, an identical protocol for
subject recruitment, sample collection and storage was
followed. Detailed information on the subject recruit-
ment, baseline data, and blood collection protocols have
been reported previously [22]. All participants gave
written, informed consent for data and biospecimen
collection and storage, as well as follow-up. The study
was approved by the local ethics committees and the
Institutional Review Board of the International Agency
for Research on Cancer (IARC, Lyon, France). During
prospective follow-up of the EPIC cohort, a very large
number (>11,000) of newly diagnosed, invasive breast
cancer cases were confirmed histologically or cytologi-
cally as primary breast cancers according to the Inter-
national Classification of Diseases for Oncology, Second
Edition (ICD-O-2) and included all breast cancer sub-
sites (ICD C50.0-C50.9). A representative subset of these
cases was used for studies comparing a variety of
biomarker measurements with a set of control subjects,
matching the cases by recruitment centre. Incident pa-
tients with cancer were identified at regular intervals
through population-based cancer registries (in Denmark,
Italy except Naples, the Netherlands, Norway, Spain,
Sweden, and the United Kingdom) or by active follow-
up (France, Germany, Greece, and Naples), which
involved a combination of methods, including a review
of health insurance records, cancer and pathology reg-
istries, and direct contact with participants and their
next-of-kin.
For the purpose of this study, we included 960 fe-
males from the EPIC cohort including 480 incident
breast cancer cases. Our main criteria for selection of
case/control pairs included: (1) a balanced representa-
tion of the main subtypes of breast cancer, and (2)
representation of recruiting centres. One control
participant was randomly assigned for each patient with
breast cancer from appropriate risk sets consisting of all
cohort participants alive and free of cancer (except for
non-melanoma skin cancer) at the time of diagnosis
(and hence, age) of the index case. Matching criteria
were: centre, length of follow-up, age at blood collection
(3 months relaxed up to 2 years for sets without avail-
able controls), time of blood collection, fasting status,
menopausal status, menstrual cycle day and current use
of contraceptive pill/hormone replacement therapy.
S. Ambatipudi et al. / European Journal of Cancer 75 (2017) 299e307302Twenty technical replicates were included to compare
inter- and intra-array batch variation. Technical repli-
cates and 38 samples or their matched counterparts
which failed the quality control criteria were excluded
from the analysis leaving 902 participants (451 controls
and 451 cases) (Table 1).
2.2. Bisulfite conversion and genome-wide DNA
methylation analysis
The DNA was isolated as per the standard DNA
extraction procedure from the from the buffy coat
samples (Autopure LS, Qiagen). DNA methylome
profiling was carried out using Illumina Infinium
HumanMethylation450 (HM450) as previously
described [23].
2.3. Bioinformatics analysis
Data preprocessing and analyses were performed using
R 3.2.3 (https://www.r-project.org/) and Bioconductor
3.2 [24] as described before [23]. DNAm level was
described as a b value, which is a continuous variable
ranging between 0 (no methylation) and 1 (fullTable 1
Characteristics of incident breast cancer and control participants at
baseline (i.e.time of blood collection).
All samples
Controls (%) Cases (%)
Sample size 451 451
Mean methylation (in %) 51.86 51.82
Age (years)
Mean (SD) 52.3 (8.94) 52.3 (8.97)
Median 53.4 53.5
Alcohol consumption (g/d)
Mean(SD) 8.2 (11.82) 10.0 (12.98)
Age at menarche
Mean (SD) 12.9 (1.34) 12.7 (1.59)
BMI
Mean (SD) 25.5 (4.22) 26.0 (4.72)
Physical activity (Cambridge index)
Sedentary 99 (22.0) 121 (26.8)
Moderately sedentary 187 (41.5) 178 (39.5)
Moderately active 76 (16.9) 87 (19.3)
Active 78 (17.3) 62 (13.7)
Missing 11 (2.4) 3 (0.7)
Hormone receptor status
ERþ/PRþ/Her2þ e 85 (18.8)
ERþ/PRþ/Her2e e 290 (64.3)
ER/PR/Her2e e 76 (16.9)
Country
Italy 160 (35.5) 160 (35.5)
Spain 27 (6.0) 27 (6.0)
UK 38 (8.4) 38 (8.4)
The Netherlands 66 (14.6) 66 (14.6)
Greece 25 (5.5) 25 (5.5)
Germany 135 (29.9) 135 (29.9)
SD: Standard deviation; ER: oestrogen receptor; PR: progesterone
receptor; Her2: human epidermal growth factor receptor 2; BMI: body
mass index.methylation). To avoid spurious associations, we
excluded the cross-reactive probes and probes over-
lapping with a known single nucleotide polymorphism
(SNPs) with a minor allele frequency of at least 5% in
the overall population (European ancestry, [25]), leaving
423,066 probes. In any given sample, probes with a
detection P-value (a measure of an individual probe’s
performance) of more than 0.05 were assigned missing
status. If a probe was missing in more than 5% of
samples, it was excluded from all samples. According to
this criterion, we excluded 1483 probes, leaving 421,583
probes available for the analyses. We applied colour bias
correction followed by quantile and beta-mixture
quantile normalisation (BMIQ) to align Type I and
Type II probe distributions [26].
2.4. White blood cell count estimates
Quantile normalised data were used to infer blood cell
proportions. We estimate blood cell counts using two
different software tools. First, Houseman’s estimation
method [27] was used to estimate the proportions of
CD8þ T cells, CD4þ T, natural killer, B cells, and
granulocytes (also known as polymorphonuclear leuco-
cytes). Second, the advanced analysis option of the
epigenetic clock software [4,14] was used to estimate the
percentage of exhausted CD8þ T cells (defined as
CD28-CD45RA-) and the number (count) of naı̈ve
CD8þ T cells (defined as CD45RA þ CCR7þ). We and
others have shown that the estimated blood cell counts
have moderately high correlations with corresponding
flow cytometric measures [27,28]. For example, flow
cytometric measurements correlate strongly with
DNAm-based estimates: r Z 0.63 for CD8þ T cells,
r Z 0.77 for CD4þ T cells, r Z 0.67 for B cell, r Z 0.68
for naı̈ve CD8þ T cell, r Z 0.86 for naı̈ve CD4þ T, and
r Z 0.49 for exhausted CD8þ T cells [28].
2.5. Global and mean methylation analysis
For the global DNAm analyses, mean methylation of
the DNAm probes (421,583) was calculated for cases
and control samples. Human cancers are characterised
by global hypomethylation and a loci-specific DNA
hypermethylation [29]. We hypothesised that DNA
methylation of probes would vary based on their phys-
ical location. To this end, the probes were classified into
different categories either reflecting their physical loca-
tion in relation to CpG islands (island, shore, shelf and
open sea) or based on a functional criterion (DP: distal
promoter, DS: distal sequence, GB: gene body, IG:
intergenic, and PP: proximal promoter) as previously
described [30]. A CpG shore is defined as the area 2 kb
on either side of the CpG island, and a CpG shelf is
defined as the area 2 kb outside of the CpG shore
[31,32]. While the regions in the genome containing
isolated CpG sites outside CpG islands, shores and
Table 2
Association between global methylation and breast cancer risk by CpG
genomic features.
Context # CpGs Std. dev. OR (95% CI)a P value
All CpG sites 421 583 3.45E-04 1.09 (0.94e1.25) 0.21
Islands 130 982 5.87E-04 1.20 (1.03e1.40) 0.02
Open Sea 150 852 4.50E-03 1.49 (0.36e6.24) 0.58
CpG Shelf 40 948 4.88E-04 0.89 (0.78e1.02) 0.10
context Shore 98 801 5.40E-04 1.00 (0.87e1.16) 0.97
Distal promoter 19 990 5.42E-04 1.06 (0.92e1.21) 0.44
Distal sequence 7828 6.68E-04 0.96 (0.84e1.09) 0.52
Genic Gene Body 168 460 3.80E-04 1.02 (0.89e1.18) 0.76
context Intergenic 56 903 5.35E-04 1.02 (0.89e1.17) 0.76
Proximal
promoter
168 337 5.26E-04 1.15 (0.99e1.34) 0.07
a Odds ratio and confidence interval were calculated per 1 standard
deviation. Odds ratios were adjusted for body mass index (BMI)
(continuous variable) and daily alcohol intake. OR- Odds ratio, CI:
confidence interval.
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referred to as open seas [33].
2.6. Epigenetic clock of ageing
The epigenetic clock is a prediction method of chrono-
logical age based on the DNAm levels of 353 CpGs [4].
The predicted (estimated) age resulting from the epige-
netic clock is referred to as ‘DNA methylation age’. In
IEAA, epigenetic age acceleration is defined as the
DNAm age left unexplained by chronological age where
intrinsic denotes a modification to this concept. In addi-
tion to adjusting for chronological age, IEAAalso adjusts
the DNAm age estimate for blood cell count estimates,
arriving at a measure that is unaffected by both variation
in chronological age and blood cell composition.
We focussed on IEAA in our blood-based methyl-
ation study as this measure of age acceleration is
significantly correlated with epigenetic age acceleration
in (non-malignant) female breast tissue [9].
Formally, IEAA is defined by regressing DNAm age
on chronological age and seven measures of blood cell
count abundances: naive CD8 T cells, exhausted CD8 T
cells (defined as CD28-CD45RA-), plasma blasts, CD4 T
cells, NK cells, monocytes, granulocytes. IEAA is auto-
matically calculated using the advanced analysis option
of the epigenetic clock software (where IEAA is denoted
as ‘AAHOAdjCellCounts’). A positive or negative value
of IEAA indicates that the woman is either older or
younger than expected based on chronological age at the
time of the blood draw.
2.7. Statistical analysis
For the mean methylation analysis, average methylation
over all probes within each category was calculated and
the odds ratios (per one standard deviation of global
methylation) were estimated by conditional logistic
regressionmodel with caseecontrol status as the outcome
and the epigenome-wide methylation measurement as
continuous predictor adjusting for surrogate variables
(technical batch effects such as sample plate, array chips),
alcohol consumption (g/day) and bodymass index (BMI)
as continuous variable.
Odds ratios (ORs) for breast cancer and 95% CIs were
calculated by using logistic regression for IEAA. Initial
analysis was done using unconditional logistic regression
to allow calculation of OR. Multivariate logistic regres-
sion was performed by including known breast cancer
risk factors including alcohol consumption (g/day), full
term pregnancy (ever/never), BMI (as continuous vari-
able and as categorical variable: underweight, normal,
overweight and obese), level of education (none, primary,
technical/profession, secondary, higher education), age at
menarche, Cambridge physical activity index (inactive,
moderately inactive, moderately active and active) strat-
ified by clustering variable. A stratified multivariateconditional logistic regression analysis based on the
menopausal status was performed using the aforemen-
tioned models.3. Results
3.1. Baseline characteristics
The baseline characteristics of samples at the time of
recruitment are listed in Table 1. Women were between
26 and 73 years of age with a mean age of 52.3 years for
cases and controls. The majority of breast cancer cases
were hormone receptor (ER and PR) positive (83%)
while 17% of the breast cancers were triple negative
(Table 1). There was a very high correlation between the
intra- and interplate technical replicates (average cor-
relation coefficient r2 Z 0.98 and 0.97, respectively, data
not shown).3.2. Hypermethylation of CpG islands is associated with
breast cancer risk
We compared the global mean methylation across
421,583 probes and observed no difference between
prospectively collected cases and matched controls
(51.82% versus 51.86%, P Z 0.68). Our analysis showed
that each unit (95% CI/1SD, 1.03e1.40, P Z 0.02) in-
crease in methylation at CpG island sites increased the
risk of being a case by 20% (Table 2). While P < 0.05, it
should be noted that the results would be marginally
significant allowing for four subsets (CpG islands, CGI
shores, CGI shelves, and open sea). No change in breast
cancer risk was observed for other regions (shore, shelf
and open sea) (Table 2), nor did we find an association
of individual CpG site or region with breast cancer
status.
Table 3






IEAA 1.04 (1.007e1.075) 1.04 (1.007e1.076)
Premenopausal samples
IEAA 1.00 (0.9572e1.06) 1.00 (0.9510e1.056)
Postmenopausal samples
IEAA 1.06 (1.019e1.11) 1.07 (1.020e1.11)
OR: Odds Ratio; CI: Confidence Interval; IEAA: Intrinsic Epigenetic
Age Acceleration.
a Odds ratios were adjusted for physical activity (inactive, moder-
ately inactive, moderately active and active).
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methylation age acceleration
Epigenetic age had a strong positive correlation with
chronological age in both case and control samples
(Fig. 1a). We observed a marginally significant differ-
ence in age acceleration between prospective cases
compared to matched controls (Fig. 1b, P Z 0.05,
Supplementary Fig. 1). Stratified analysis based on time
from blood collection to disease diagnosis revealed that
prospective breast cancers exhibited age acceleration 10
years prior to diagnosis compared to matched control
samples (Fig. 1c, P Z 0.01).
A conditional logistic regression model that relates
breast cancer status to IEAA showed that IEAA was
associated (Table 3) with breast cancer status. The re-
sults were not attenuated after adjusting for known
breast cancer factors (Supplementary Table 1). Each
unit increase in IEAA led to 4% increased odds of being
a breast cancer case (OR, 1.04; 95% CI, 1.007e1.076,
P Z 0.016) (Table 3). IEAA follows an approximately
normal distribution with mean zero, variance Z 28.2,
standard deviation of 5.31. The following quantiles
describe the empirical distribution of IEAA:
minimum Z 24.2, maximum 24.4, median Z 0.12,
first quartile Z 3.0, third quartile Z 3.0. Thus, 25% of
women had an IEAA value > 3.Fig. 1. Epigenetic clock analysis. a) DNA methylation age (y-axis)
versus chronological age (x-axis). Points correspond to female
subjects. Red indicates breast cancer case, black control. The
dashed line indicates a regression line, b) epigenetic age accelera-
tion versus breast cancer status. Each bar plot depicts the mean
value, standard deviation and reports a non-parametric group
comparison test p-value (Wilcoxon test), c) epigenetic age accel-
eration versus breast cancer status (developed within 10 years post
blood draw). Each bar plot depicts the mean value, standard
deviation and reports a non-parametric group comparison test p-
value (Wilcoxon test). (For interpretation of the references to
colour in this figure legend, the reader is referred to the web
version of this article.)None of the blood cell count measures were associ-
ated with disease status in prediagnostic blood samples
(Supplementary Fig. 2). Interestingly, high physical ac-
tivity was associated with decreased odds of being a
breast cancer case (Supplementary Table 1).
A recent study demonstrated that menopause has a
weak but statistically significant effect on epigenetic age
acceleration. Further, menopause has been known to
accelerate age-related diseases including breast cancer
[34,35]. To adjust for menopausal status, we evaluated
the association between IEAA and breast cancer in
separate strata defined by menopausal status (premen-
opausal and postmenopausal). The baseline character-
istics of premenopausal and postmenopausal breast
samples are shown in Supplementary Table 2. We
observed a positive correlation between epigenetic and
chronological age in postmenopausal samples (Fig. 2a).
Stratified analysis of postmenopausal breast cancers
based on the lead-time between blood collection and
cancer diagnosis revealed that breast cancers had a
higher IEAA compared to non-cancer samples (Fig. 2b,
Supplementary Fig. 3).
A very high value of IEAA Z 10 is associated with a
doubling of odds of developing postmenopausal breast
cancer (OR Z 1.97 (1.22e2.83) calculated as 1.0710
from our multivariate logistic regression model Table 3).
Twenty-five percent of all women exhibit an age accel-
eration larger than 3 which is associated with 22% in-
crease in the odds of developing postmenopausal breast
cancer (OR Z 1.22 (1.06e1.37) calculated as 1.073).
We found that breast cancer that developed within 10
years from date of recruitment had a stronger associa-
tion with IEAA (Fig. 2c). However, the results of this
secondary analysis should be interpreted with caution
due to an inflated false positive rate resulting from
multiple comparisons. We did not observe such associ-
ations in premenopausal breast samples (Supplementary
Figs. 4, 5). Similar to our findings in all breast samples,
high physical activity was associated with decreased
odds of being a breast cancer case in postmenopausal
women (Supplementary Table 3).
Fig. 2. Epigenetic clock analysis for postmenopausal samples.
a) DNA methylation age (y-axis) versus chronological age (x-axis).
Points correspond to female subjects. Red indicates breast cancer
case, black control. The dashed line indicates a regression line; b)
epigenetic age acceleration versus breast cancer status. Each bar
plot depicts the mean value, standard deviation and reports a non-
parametric group comparison test p-value (Wilcoxon test); c)
epigenetic age acceleration versus breast cancer status (developed
within 10 years post blood draw). Each bar plot depicts the mean
value, standard deviation, and reports a non-parametric group
comparison test p-value (Wilcoxon test). (For interpretation of the
references to colour in this figure legend, the reader is referred to
the web version of this article.)
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ciation between IEAA and incident postmenopausal
breast cancers (OR, 1.07; 95% CI, 1.020e1.11,
PZ 0.003). By contrast, no significant association could
be observed for incident premenopausal breast cancers
(OR, 1.00; 95% CI, 0.9510e1.056, P Z 0.94) (Table 3).
4. Discussion
Using a rigorous and large-scale nested prospective
caseecontrol study, we demonstrate that: (1) IEAA
in blood increases the odds of developing post-
menopausal breast cancers and (2) genome-wide
hypermethylation in CpG islands is associated with
incident breast cancer cases. While several articles have
studied blood methylation data versus breast cancer risk
[36e39], it appears that ours is the first study to detect a
weak but significant association of IEAA with breast
cancer susceptibility. Our study stands out in terms of its
large sample size, its use of a robust epigenome wide
technology (Illumina 450K array), the careful matching
of breast cancer cases with controls in a prospective
caseecontrol study, and its use of a powerful epigenetic
biomarker of ageing, which is independent of blood cell
counts (IEAA).
Our finding regarding the association between global
CpG island methylation levels and breast cancer risk is
congruent with the findings from our earlier retrospectivestudy on breast cancer [39] and supports the notion that
regulatory regions of the genome are often hyper-
methylated in cancer cells [29]. It is noteworthy that we
observed CpG island hypermethylation in blood tissue
samples of incident breast cancer patients. Several
epidemiological caseecontrol studies have reported
global genomic hypomethylation in peripheral blood of
cancer patients, suggesting a systemic effect of hypo-
methylation on disease predisposition [40,41]. In addi-
tion, two recent studies reported a lower global
methylation levels in prospectively collected blood sam-
ples from breast cancer cases compared to controls
[38,42]. However, we did not find any change in global
DNAm levels between cases and controls. These dis-
crepancies may be due to technical and biological varia-
tions attributable to the low power of the studies.
Epigenetic changes are ubiquitous in primary breast
cancers although the role of deregulation of the epi-
genome is largely unknown. It has been suggested that a
gradual accumulation of methylation changes (‘epige-
netic drift’) may occur through stochastic events,
resulting in clonal expansion of the stem/progenitor
cells, and that this process may contribute to the age-
associated increase in risk of developing breast cancer
[43e45]. DNAm age is highly correlated to chronolog-
ical age across sorted cell types (CD4 T cells, monocytes,
B cells, glial cells, neurons), complex tissues (e.g. blood)
and organs (brain, breast, kidney, liver, lung) [4]. Our
findings were consistent with the previous studies in
different tissues [4,16]. The epigenetic clock derived
from the DNAm age is robust with respect to the batch
effects and can be applied to all Illumina array plat-
forms: the EPIC chip (850K), the Illumina 450K array
and the 27K array [4] and possibly measures a cell
intrinsic and tissue independent epigenetic drift [46]. For
blood derived DNA measured on the Illumina 450K
array, the epigenetic clock algorithm provides not only
several measures of age acceleration but also estimates
of blood cell counts. One of the major concerns
regarding age-associated DNAm signatures is the in-
fluence of tissue’s cellular composition which may alter
with age. We found no differences in leucocyte sub-
populations between cases and controls. By definition,
our intrinsic measure of epigenetic age acceleration
(IEAA) is not confounded by changes in the proportion
of blood cell counts (Methods). We focussed on IEAA
as it has been shown to be correlated with epigenetic age
acceleration in breast tissue [9]. Future research could
investigate whether epigenetic age acceleration of breast
tissue is predictive of breast cancer.
We can only speculate when it comes to explaining
why IEAA was only predictive of postmenopausal
breast cancer but not of premenopausal breast cancer.
Breast cancers developing in postmenopausal women
are influenced by specific polymorphisms in endogenous
steroid hormone metabolic pathways and exogenous
administration of hormones at menopause (hormone
S. Ambatipudi et al. / European Journal of Cancer 75 (2017) 299e307306replacement therapy). Our observed age acceleration in
postmenopausal breast cancers might reflect differences
in hormone exposure. In this context, it is noteworthy
that both natural and surgical menopause are associated
with an increase in intrinsic age acceleration [18]. In
addition, age-associated compromised detoxification,
DNA repair mechanisms and immune surveillance may
add to the endogenous factors which could lead to
postmenopausal breast cancer development [1]. It is
unlikely that smoking and BMI confound the relation-
ship between epigenetic age and breast cancer risk
because : (1) BMI and smoking have only a very weak
effect on the epigenetic age acceleration of blood tissue
(correlation r < 0.10) [16,20], and (2) we could detect
accelerated ageing effects in multivariate regression
models that adjusted for these potential confounders.
Our results based on a prospective study cohort points
to a higher rate of ageing in the blood samples from
individuals who develop breast cancer compared to the
controls. While the results from our epigenetic age
analysis are biologically meaningful, the association
between DNAm age and disease risk is probably too
weak for prognostic purposes.
In the present study, we demonstrated that a surro-
gate tissue (blood) captures accelerated ageing effects
and relates to an effector (breast cancer) of ageing. We
have demonstrated that IEAA was associated with
postmenopausal breast cancer susceptibility and identi-
fied potential epigenetics-based biomarkers for risk
stratification. Because menopause has been known to
accelerate age-related diseases including cancer, our
finding also suggest potential underlying mechanism and
provides biological plausibility to the association be-
tween menopause and cancer risk. Further research
aimed at understanding epigenome deregulation in
cancer causation, risk stratification and the mechanism
underlying accelerated epigenetic clock is warranted.
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